

<!-- Start Fragment -->

RESULT 8

AAA15967

ID AAA15967 standard; cDNA; 2054 BP.

XX

AC AAA15967;

XX

DT 12-JUN-2000 (first entry)

XX

DE Human protein clone HP02419 full length coding sequence.

XX

KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy; ss.

XX

OS Homo sapiens.

XX

PN WO200005367-A2.

XX

PD 03-FEB-2000.

XX

PF 22-JUL-1999; 99WO-JP003929.

XX

PR 24-JUL-1998; 98JP-00208820.

PR 07-AUG-1998; 98JP-00224105.

PR 25-AUG-1998; 98JP-00238116.

PR 09-SEP-1998; 98JP-00254736.

PR 29-SEP-1998; 98JP-00275505.

XX

PA (SAGA) SAGAMI CHEM RES CENT.

PA (PROT-) PROTEGENE INC.

XX

PI Kato S, Kimura T;

XX

DR WPI; 2000-182694/16.

DR P-PSDB; AAY94879.

XX

PT Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
 PT sclerosis, rheumatoid arthritis, cancer; anemia, and stroke.

XX

PS Claim 4; Page 294-296; 351pp; English.

XX

CC This sequence encodes a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other

CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours

XX

SQ Sequence 2054 BP; 470 A; 489 C; 484 G; 611 T; 0 U; 0 Other;

Query Match 97.6%; Score 930.8; DB 3; Length 2054;
 Best Local Similarity 99.8%; Pred. No. 1.3e-214;
 Matches 932; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	21	CACATGGCCGAGTCCGCCCGCCCCCTCCCGTCCCGCGCGCTGCAGCCGTCGCCTTCGG	80
Db	1	CACATGGCCAAGTCCGCCCGCCCCCTCCCGTCCCGCGCGCTGCAGCGGTTCGCCTTCGG	60
Qy	81	AGCGAAGGGTACCGACCCGGCAGAAGCTCGGAGCTCTCGGGGTATCGAGGAGGCAGGCC	140
Db	61	AGCGAAGGGTACCGACCCGGCAGAAGCTCGGAGCTCTCGGGGTATCGAGGAGGCAGGCC	120
Qy	141	GCGGGCGCACGGGCGAGCGGGCCGGGAGCCGGAGCGGCGGAGGAGCCGGCAGCAGCGGCG	200
Db	121	GCGGGCGCACGGGCGAGCGGGCCGGGAGCCGGAGCGGCGGAGGAGCCGGCAGCAGCGGCG	180
Qy	201	CGGCGGGCTCCAGGCGAGGCGGTTCGACGCTCCTGAAAACCTGCGCGCGCGCTCGCGCCAC	260
Db	181	CGGCGGGCTCCAGGCGAGGCGGTTCGACGCTCCTGAAAACCTGCGCGCGCGCTCGCGCCAC	240
Qy	261	TGCGCCCGGAGCGATGAAGATGGTCGCGCCCTGGACGCGGTTCTACTCCAACAGCTGCTG	320
Db	241	TGCGCCCGGAGCGATGAAGATGGTCGCGCCCTGGACGCGGTTCTACTCCAACAGCTGCTG	300
Qy	321	CTTGTGCTGCCATGTCCGCACCGCACCATCCTGCTCGGCGTCTGGTATCTGATCATCAA	380
Db	301	CTTGTGCTGCCATGTCCGCACCGCACCATCCTGCTCGGCGTCTGGTATCTGATCATCAA	360
Qy	381	TGCTGTGGTACTGTTGATTTTATTGAGTGCCCTGGCTGATCCGGATCAGTATAACTTTTC	440
Db	361	TGCTGTGGTACTGTTGATTTTATTGAGTGCCCTGGCTGATCCGGATCAGTATAACTTTTC	420
Qy	441	AAGTTCTGAACTGGGAGGTGACTTTGAGTTCATGGATGATGCCAACATGTGCATTGCCAT	500

```
Db      421 AAGTTCTGAACTGGGAGGTGACTTTGAGTTCATGGATGATGCCAACATGTGCATTGCCAT 480
Qy      501 TGCGATTTCTCTTCTCATGATCCTGATATGTGCTATGGCTACTTACGGAGCGTACAAGCA 560
      |||
Db      481 TGCGATTTCTCTTCTCATGATCCTGATATGTGCTATGGCTACTTACGGAGCGTACAAGCA 540
Qy      561 ACGCGCAGCCTGGATCATCCCATTCTTCTGTTACCAGATCTTTGACTTTGCCCTGAACAT 620
      |||
Db      541 ACGCGCAGCCTGGATCATCCCATTCTTCTGTTACCAGATCTTTGACTTTGCCCTGAACAT 600
Qy      621 GTTGGTTGCAATCACTGTGCTTATTTATCCAACTCCATTAGGAATACATACGGCAACT 680
      |||
Db      601 GTTGGTTGCAATCACTGTGCTTATTTATCCAACTCCATTAGGAATACATACGGCAACT 660
Qy      681 GCCTCCTAATTTTCCCTACAGAGATGATGTCATGTCAGTGAATCCTACCTGTTTGGTCCT 740
      |||
Db      661 GCCTCCTAATTTTCCCTACAGAGATGATGTCATGTCAGTGAATCCTACCTGTTTGGTCCT 720
Qy      741 TATTATTCTTCTGTTTATTAGCATTATCTTGACTTTTAAGGGTTACTTGATTAGCTGTGT 800
      |||
Db      721 TATTATTCTTCTGTTTATTAGCATTATCTTGACTTTTAAGGGTTACTTGATTAGCTGTGT 780
Qy      801 TTGGAAGTCTACCGATACATCAATGGTAGGAACCTCCTCTGATGTCCTGGTTTATGTTAC 860
      |||
Db      781 TTGGAAGTCTACCGATACATCAATGGTAGGAACCTCCTCTGATGTCCTGGTTTATGTTAC 840
Qy      861 CAGCAATGACACTACGGTGCTGCTACCCCGTATGATGATGCCACTGTGAATGGTGCTGC 920
      |||
Db      841 CAGCAATGACACTACGGTGCTGCTACCCCGTATGATGATGCCACTGTGAATGGTGCTGC 900
Qy      921 CAAGGAGCCACCGCCACCTTACGTGTCTGCCTAA 954
      |||
Db      901 CAAGGAGCCACCGCCACCTTACGTGTCTGCCTAA 934
<!-- EndFragment -->
```